ABSTRACT
Liver fibrosis(LF),as a global public health issue,has become increasingly recognized and valued by the more and more publics.Almost all types of chronic liver diseases can cause LF.The active and effective interventions can delay or prevent the progression of LF disease conditions,and even achieve partial normalization outcome of that.The conventional"gold standard"of diagnosing LF is liver biopsy,but this examination method is invasive,which exists disadvantages included a certain risks and the lower patient acceptance.Therefore,it is difficult to widely carry out this examination in clinical practice.Imaging examination,as a non-invasive assessment method for LF,can achieve quantitative,qualitative and functional detection,which can provide convenience for diagnosing and treating LF.Common imaging examination methods include ultrasound,computed tomography(CT),magnetic resonance imaging(MRI),nuclear medicine,etc.This review summarizes the relevant researches that imaging technology assesses LF,and discusses the important role of that in clinical diagnosis,treatment and scientific research.
ABSTRACT
Abstract Introduction: Cirrhosis of the liver is a significant cause of morbidity and mortality in Latin America; the increased prevalence of metabolic syndrome in our population could be changing the epidemiological profile of patients with advanced chronic liver disease. Aim: To characterize a group of patients with cirrhosis of the liver at an outpatient hepatology care center in Cartagena de Indias, Colombia, and determine the contribution of nonalcoholic steatohepatitis (NASH) as an etiological factor in this population. Materials and methods: Retrospective, cross-sectional, analytical study. All patients who attended the hepatology follow-up with a diagnosis of cirrhosis of the liver were in the six-monthly follow-up protocol that included screening for hepatocellular carcinoma (HCC) and esophageal varices. Results: 346 patients were included, most were women (54.3 %). The first and second causes of cirrhosis were cryptogenic (35 %) and NASH (30.9 %), respectively, followed by viral hepatitis (17 %) and autoimmune diseases (9 %). Of these patients, 87.4 % were within categories A and B of the Child-Turcotte-Pugh score, and only 12.5 % (33 patients) were in stage C. Also, 60 % had at least one clinical decompensation, 38 % a history of variceal hemorrhage, and 4 % a diagnosis of HCC; 80.6 % of patients with NASH cirrhosis had diabetes, and 46.7 % were overweight. Conclusion: NASH cirrhosis is an emerging cause of advanced chronic liver disease in Colombia.
Resumen Introducción: la cirrosis hepática es una importante causa de morbimortalidad en América Latina; el incremento de la prevalencia del síndrome metabólico en nuestra población podría estar cambiando el perfil epidemiológico de los pacientes con enfermedad hepática crónica avanzada. Objetivos: caracterizar un grupo de pacientes con cirrosis hepática y determinar la contribución de la esteatohepatitis no alcohólica (NASH) como factor etiológico de esta población en la ciudad de Cartagena de Indias, Colombia, en un centro de atención ambulatoria de hepatología. Métodos: estudio retrospectivo, transversal, analítico. Se incluyeron todos los pacientes que acudieron al seguimiento de hepatología con diagnóstico de cirrosis hepática que se encontraban en el protocolo de seguimiento semestral que incluía el cribado de hepatocarcinoma y várices esofágicas. Resultados: se incluyeron 346 pacientes. La mayoría fueron mujeres (54,3 %). La primera y segunda causa de cirrosis fue la criptogénica (35 %) y la NASH (30,9 %), respectivamente; seguidas de las hepatitis virales (17 %) y enfermedades autoinmunes (9 %). De estos pacientes, el 87,4 % se encontraba dentro de las categorías A y B de la escala pronóstica de Child-Turcotte-Pugh, y solo el 12,5 % (33 pacientes) en estadio C. El 60 % había presentado al menos una descompensación clínica, 38 % tenía antecedentes de hemorragia por várices y 4 %, diagnóstico de hepatocarcinoma. El 80,6 % de los pacientes con cirrosis NASH era diabético y el 46,7 % tenía exceso de peso. Conclusión: La cirrosis NASH es una causa emergente de enfermedad hepática crónica avanzada en Colombia.
Subject(s)
Humans , Male , Female , Metabolic Syndrome , Non-alcoholic Fatty Liver Disease , Liver , Liver Cirrhosis , Varicose Veins , Hepatitis , Liver DiseasesABSTRACT
Abstract Introduction: Severe acute respiratory syndrome type 2 coronavirus infection (SARS-CoV-2) is receiving the most attention now. The asymptomatic elevation of transaminases is typical in the liver, and liver involvement varies from 14 % to 78 %. The assessment of liver comorbidities is scarce, with prevalence ranging between 2 % and 11 %. Aim: To describe the behavior of a cohort of patients with liver diseases who fell ill with coronavirus disease 2019 (COVID-19). Materials and methods: This retrospective observational study analyzed the behavior of a cohort of patients with liver diseases who fell ill with COVID-19. Results: 543 patients became ill with COVID-19, of which 300 were women (55.3 %). The median age at diagnosis of liver disease was 52 years. The leading causes of liver disease were nonalcoholic steatohepatitis (49.5 %), cholestatic disease (7.7 %), and hepatitis C and B viruses (6.3 %). Alanine aminotransferase (ALT) had a median of 52 U/L (interquartile range [IQR]: 30-98) and aspartate aminotransferase (AST) 32 U/L (IQR: 23-62). Mortality due to viral infection was 5.7 %, with an incidence rate of 2.9 (95 % confidence interval [CI]: 2-4.2). Conclusions: It is a retrospective study but, until the preparation of the manuscript, it had been the first cohort in Colombia to describe the behavior of liver diseases in patients who become ill with COVID-19. No statistically significant differences were found between the causes of liver disease that confer a higher risk of mortality; however, having decompensated cirrhosis is the only condition related to mortality.
Resumen Introducción: la infección por coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) concentra la mayor atención en el momento. En el hígado es frecuente la elevación asintomática de transaminasas y la afectación hepática varía del 14 % al 78 %. La evaluación de las comorbilidades hepáticas es escasa, con prevalencias que oscilan entre el 2 % y el 11 %. Objetivo: describir el comportamiento de una cohorte de pacientes con enfermedades hepáticas que presentaron el coronavirus de 2019 (COVID-19). Materiales y métodos: estudio observacional retrospectivo que analizó el comportamiento de una cohorte de pacientes con hepatopatías que enfermaron por COVID-19. Resultados: 543 pacientes padecieron por COVID-19, de los cuales 300 fueron mujeres (55,3 %). La mediana de edad al diagnóstico de la enfermedad hepática fue de 52 años. Las principales causas de las hepatopatías fueron esteatohepatitis no alcohólica (49,5 %), enfermedad colestásica (7,7 %), virus de la hepatitis C y B (6,3 %). La alanina-aminotransferasa (ALT) presentó una mediana de 52 U/L (rango intercuartílico [RIC]: 30-98) y aspartato-aminotransferasa (AST) 32 U/L (RIC: 23-62). La mortalidad por la infección viral fue del 5,7 % con una tasa de incidencia de 2,9 (intervalo de confianza [IC] 95 %: 2-4,2). Conclusiones: es un estudio de carácter retrospectivo; sin embargo, hasta la elaboración del manuscrito es la primera cohorte en Colombia en describir el comportamiento de las enfermedades hepáticas en pacientes que enferman de COVID-19. No se encontraron diferencias estadísticamente significativas entre las causas de hepatopatía que confieran un mayor riesgo de mortalidad; sin embargo, tener una descompensación de cirrosis es la única condición que tiene una relación con la mortalidad.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Fibrosis , Retrospective Studies , SARS-CoV-2 , COVID-19 , Prevalence , Causality , Mortality , Hepatitis C , Diagnosis , Non-alcoholic Fatty Liver Disease , Liver DiseasesABSTRACT
Objective To analyze the blood of patients with hepatitis B cirrhosis complicated with iron deficiency anemia(IDA).Methods The 100 cases with hepatitis B cirrhosis complicated with IDA and hepatitis B cirrhosis complicated with non-iron deficiency anemia (NIDA) were recruited in our hospital from December 2013 to May 2015,and were divided into observation group (50 cases) and control group(50 cases) according to whether complicated with IDA.The liver function,blood routine,liver cirrhosis patients with coagulation test and measurement of the platelet parameters of two groups of patients were detected and analyzed.Results After treatment,no statistically significant difference were observed the levels of albumin,bilirubin,bile acid and alkaline phosphatase between two groups (P>0.05).The levels of alanine amino transferase (ALT),gamma glutamyltransferase (GGT) in the observation group were significantly higher than those in the control group(P0.05).The prothrombin time (PT),International normalized ratio (INR),activated partial thromboplastin time (APTT),thrombin time (TT) of observation group were higher than the control group(P0.05).Conclusion The detection of blood in patients with hepatitis B cirrhosis complicated with IDA is of great significance in the evaluation of the degree of liver damage and the diagnosis of the disease,which is worthy of clinical application in the future.
ABSTRACT
Objective To evaluate the efficacy of lamivudine and adefovir in the treatment of patients with decompensated hepatitis B cirrhosis . Methods 90 cases of patients with hepatitis B cirrhosis of the liver decompensation period from August 2013 to June 2015 in our hospital were researched.According to the random number table method divided into observation group and control group , each of 45 cases, the total course of treatment was one year.The observation group was treated with lamivudine combined with adefovir dipivoxil , control group was treated with lamivudine.The clinical effect, the indexes of liver function, the changes of HBV-DNA and Child-pugh score were compared between the two groups after treatment.Results After treatment, the total effective rate of the observation group ( 93.33%) was obviously higher than that of control group (48.89%), the difference was statistically significant (P<0.05), the observation group alanine amino acid, total bilirubin, aspartate aminotransferase were (71.23 ±21.32)U/L, (28.32 ±4.65)Umol/lL, (4.65 ±9.25)U/L, they were significantly lower than control group (111.54 ±16.25)U/L, (46.53 ±4.89 ) Umol/L, ( 4.89 ±12.11 ) U/L, the observation group albumin ( 39.82 ±2.62 ) g/L was significantly higher than control group (35.55 ±2.22)g/L, the difference was statistically significant (P<0.05), after treatment, the observation group hepatitis b HBV DNA levels, Dhild pugh score (2.78 ±0.45)log10 copies/mL, (6.12 ±1.23) were significantly lower than the control group (3.89 ±0.65)log10 copies/mL, (7.89 ± 1.21)scores, the difference was statistically significant (P <0.05).Conclusion The combination of lamivudine and adefovir dipivoxil significantly decompensated hepatitis B cirrhosis has a curative effect, it could effectively improve the patient's liver function, Dhild-pugh score, HBV-DNA level.
ABSTRACT
HCV-related decompensated cirrhos,hypersplenism,thrombocytopenia,which not only affect the standard antiviral therapy,fail to achieve the sustained virological response(SVR),but also increase the risk of infection and bleeding.The only successful option is liver transplantation (LT),but the recurrence of HCV after LT remains to be resolved.The patients of HCV genotype 2 are suitable for splenectomy and antiviral therapy following splenectomy,which can achieved a higher SVR and reversed cirrhosis.As an effective alternative to splenectomy,the partial splenic embolization (PSE) can improve the changes of portal hemodynamics and reduce the sequelae of portal hypertension.The appearance of direct antiviral drugs (DAAs)has bring hope for those with decompensated cirrhos and whom IFN is contraindicated or tolerated poorly,those who are waiting for LT or with recurrence of hepatitis C after LT.The treatment of patients with decompensated cirrhos is as follows.
ABSTRACT
Objective To explore the risk factors and the recurrence of spontaneous bacterial peritonitis after taking intestinal probiotics.Methods Fifty-six patients with spontaneous bacterial peritonitis were randomly divided into control group and probiotics group,and each group were 28 cases.Patients in control group were treated by regular hepatoprotective drug,while in probiotics group were administrated with Jinshuangqi orally,every time 0.5 g × 4 tablets,2 times a day besides regular hepatoprotective drug.The course of the treatment was for 3 months.The symptoms and other risk factors,and the relief time were recorded.Results Incidence of spontaneous bacterial peritonitis in probiotics group and control group were 21.4% and46.4% respectively(x2 =3.784,P < 0.05).Rate of gastric ulcer were 17.9% and 42.9% respectively and the difference was significant(x2 =4.139,P < 0.05).The relief time of fever in probiotics group was (2.52 ± 0.78) d,lower than that of control group ((4.21 ± 1.34) d,t =2.029,P < 0.05).Meanwhile the relief time of abdominal tenderness was (4.02 ± 0.96) d in probiotics group,and (6.34 ± 1.27) d in control group (t =2.433,P < 0.05).Conclusion Intestinal probiotics treatment can significantly reduce the recurrence rate of spontaneous bacterial peritonitis,shorten the relief time of each symptom and reduce the incidence of other risk factors.
ABSTRACT
La hepatitis autoinmune (HAI) es una hepatopatía inflamatoria crónica y progresiva, que afecta predominantemente al sexo femenino y se caracteriza por la presencia de autoanticuerpos, elevación de aminotransferasas e hipergammaglobulinemia. Evoluciona rápidamente a cirrosis en pacientes no tratados, por lo que su diagnóstico precoz es indispensable. El propósito de este estudio es evaluar el tiempo promedio entre el inicio de los síntomas y el diagnóstico, así como su correlación con la presencia de cirrosis. Se realizó un estudio analítico, retrospectivo, no experimental. Se revisaron las historias clínicas de 51 pacientes que acudieron a la consulta de gastroenterología del hospital de niños J.M. de los Ríos desde abril de 1996 hasta septiembre de 2010 diagnosticados de HAI según criterios clínicos, serológicos e histológicos. Se excluyeron 3 pacientes por presentar patologías asociadas o estar recibiendo tratamiento inmunosupresor previo. La edad varió entre 2 y 15 años (media 8,3±3,2 DE); prevaleciendo el sexo femenino (72,9%). La clínica predominante fue ictericia (81,3%), coluria (47,9%) y dolor abdominal (39,5%). El diagnóstico se realizó en promedio 8,4 ± 7,3 meses luego del inicio de los síntomas. 50% se diagnosticó en los primeros 6 meses, de éstos 54,2% presentó cirrosis y 33,3% fibrosis. La HAI debe considerarse en pacientes pediátricos con clínica de hepatopatía inflamatoria a fin de realizar un diagnóstico oportuno y precoz debido a su rápida evolución a cirrosis
Autoimmune hepatitis (HAI) is a progressive chronic inflammatory hepatopathy with higher prevalence in females characterized by autoantibodies presence, elevation of aminotransferases and hipergammaglobulinemia. Another important characteristic is that it can develop into a rapid cirrhosis, so early diagnosis is vital. The purpose of our study is to evaluate the time spent between initial symptoms and final diagnosis, and it relation with the presence of cirrhosis. An analytic, retrospective non experimental study was performed. We reviewed the clinical records of 51 patients from April 1996 to September 2010 who attended the consultation of gastroenterology in the J. M. de los Ríos Children's Hospital with the diagnose of HAI according to clinical criteria, serological and histological. We excluded 3 patients for two reasons. 1. They were presenting associated pathologies 2. They were receiving immunosuppressive treatment. The ages vary from 2 to 15 years old (mean 8.3±3.2 ED); female prevail with (72.9%). The predominant symptoms were jaundice (81.3%), coluria (47.9%) and abdominal pain (39.5%). The diagnosis was made on average 8.4 ± 7.3 months after the beginning of the symptoms. 50% were diagnosed in the first 6 months, from these 54.2% presented with cirrhosis and 33,3% with fibrosis. HAI must be considered in pediatric patients with inflammatory hepatopathy clinical history in order to make an early and opportune diagnosis due to its rapid evolution to cirrhosis
Subject(s)
Female , Child, Preschool , Child , Liver Cirrhosis/pathology , Liver Cirrhosis/prevention & control , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/pathology , Hepatitis, Autoimmune/prevention & control , Liver Diseases , Gastroenterology , PediatricsABSTRACT
PURPOSE: D-lactate, optical isomer of L-lactate is not a human metabolite. Once the D-lactate enters the human body, it is mainly metabolized in liver. The metabolism of D-lactate can be changed in patients with decompensated liver cirrhosis with the exposure of antibiotics and the frequent trial of lactulose, if neccessory. The aim of this study is to analyze blood D-lactate level in cirrhotic patients and it's relationship with the degree of hepatic insufficiency and acid-base imbalance. METHODS: Plasma L-lactate and D-lactate levels were measured in 40 cirrhotic patients classified by Child-Pugh system with L-LDH and D-LDH with comparison of their changes before and after the use of antibiotics and lactulose(n=14). Also, acid-base disorders were analyzed in 35 cirrhotic patients, and plasma L, D-lactate levels were determined in each acid-base disorder. RESULTS: Plasma D-lactate level was not significantly elevated in cirrhotic patients compared to the control group(2.34+/-.48 mmol/L vs. 1.63+/-.26 mmol/ L, p=NS), but some patients(n=4, 10%) revealed abnormally elevated D-lactate level. The plasma L, D- lactate levels were not different in subgroups classified by Child-Pugh system as well as by underlying causes of liver cirrhosis, and plasma D-lactate level was not sugnificnatly different before and after the exposure of antibiotics and lactulose. Plasma D-lactate level was significantly increased in 3 patients with respiratory alkalosis and metabolic acidosis(12+/-.98 mmol/L) compared to others(p<0.05). CONCLUSION: These results suggest that, regardless of its decompensated degree and exposure to drugs, a subset of patients with liver cirrhosis can develop elevation of D-lactate in blood, particularly when metabolic acidosis is accompanied.